Cg Oncology Inc (CGON) Stock Price, Quote & News

Company Profile

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of pa...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 409 3700

Website: cgoncology.com

Address:

3000 Pegasus Park Drive, Suite 1640, Dallas, United States

MorganHoratio Jul. 2 at 9:49 PM

One of the strongest sectors outside of AI right now is Biotech. Oncology $TNGX Tango Therapeutics $ELVN Enliven Therapeutics $RVMD Revolution Medicines $RLAY Relay Therapeutics $CGON CG Oncology The non-AI capital cycle is shifting into oncology biotech! Smart money is layering tactical limit entry orders atop long-term Fibonacci volume floors, lock-floating high-velocity platforms commanding unassailable clinical moats. Kingpin RVMD accelerates its right-side PEG defense, scaling historic highs past $185 on unprecedented Phase 3 pancreatic cancer efficacy. It pairs with CGON anchoring a massive $1.1B liquidity fortress ahead of its late-2026 BLA filing, flanked by ELVN fresh off an upsized $400M offering and stellar leukemia trial updates. Synthetic lethality disrupter TNGX enters key Russell Growth indexes following a powerhouse $600M capital raise, while RLAY hardens its floor. The playbook: buy the FIB support dip on CGON or ride RVMD's velocity!

3 · Reply

Buy_SoFi Jul. 2 at 12:00 PM

$TLTFF <----- 👀. Keep an eye on Theralase if you're in $CGON $IBRX $ENGN and looking for an undervalued cancer cure play. FDA rolling review for Ruvidar (NMIBC) about to be announced (Q3 2026), future market leader in HSV treatment and other cancer cures... These opportunities for "100x returns" don't come around very often. $MRK

0 · Reply

BioRich Jul. 1 at 4:46 PM

$TEM Stocktwits Q2 Quarterly Filing: @BioRich Top 50 portfolio positions: 1) GUTS 2) ABVX 3) IBRX 4) ALT 5) KYTX 6) DAVE 7) CADL 8) MIST 9) UEC 10) OTLK 11) CAPR 12) TGTX 13) SABS 14) NVAX 15) LEGN 16) VKTX 17) OCUL 18) SOFI 19) BBIO 20) SGP 21) VNDA 22) SHAZ 23) NRXP 24) GPCR 25) EWTX 26) TLSA 27) SKM 28) MLTX 29) SNDX 30) JMIA 31) NKTR 32) VVOS 33) RGNX 35) ARRNF 36) CRMD 37) WVE 38) NUVB 39) SMMT 40) ANNX 41) $CGON 42) TEM 43) $IVA 44) $PSN 45) $LGND 46) IMVT 47) MPLT 48)NNE 49) ARDX 50) COGT If I own it, I believe in it. What am I missing? Hold too much? Not enough? Look forward to your feedback! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

2 · Reply

Buy_SoFi Jun. 30 at 8:37 PM

$TLTFF <--- MAJOR NEWS!!! 💥 $100 million in financing now accessible! $IBRX $CGON $ENGN $MRK

0 · Reply

forprofit12 Jun. 30 at 1:28 PM

$CGON last trading day of Q2. Weren’t results promised in Q2? Hopefully management has a calendar.

1 · Reply

justiceforb_85 Jun. 30 at 1:06 AM

$CGON re-entered. Looking forward to PIVOT-006 data. If not successful, there is a floor to cretostimogene's value.

2 · Reply

judgeyoung2 Jun. 26 at 7:07 PM

$CGON @tonyctl anything interesting in this flow ?

1 · Reply

Grinding10 Jun. 26 at 4:50 PM

$CGON $65 stock that trades in 50 cent intervals; ok👍

0 · Reply

BIgBill374 Jun. 24 at 11:41 PM

$CGON tape painting or legit sell

1 · Reply

Buy_SoFi Jun. 24 at 5:18 PM

$CGON < $TLTFF

0 · Reply

CG Oncology Slides: Investor presentation

Jun 29, 2026, 7:00 AM EDT - 5 days ago

CG Oncology Slides: Conference presentation

2026-06-25T12:55:24.000Z - 9 days ago

CG Oncology 1.15M share Block Trade priced at $66.87

2026-06-24T21:45:09.000Z - 10 days ago

CG Oncology 1.15M share Block Trade; price range $66.87-$67.87

Jun 9, 2026, 2:40 PM EDT - 25 days ago

CG Oncology Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 10:30 AM EDT - 4 weeks ago

CG Oncology Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 4:05 PM EDT - 5 weeks ago

CG Oncology to Present at Upcoming Investor Conferences in June

2026-05-26T15:52:04.000Z - 5 weeks ago

CG Oncology announces departure of president, COO Ambaw Bellete

2026-05-26T15:48:12.000Z - 5 weeks ago

Wolfe sees CG Oncology COO exit as operational, no impact to key programs

May 20, 2026, 2:35 PM EDT - 6 weeks ago

CG Oncology Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 8:00 AM EDT - 6 weeks ago

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

2026-05-19T10:11:37.000Z - 6 weeks ago

CG Oncology initiated with a Peer Perform at Wolfe Research

2026-05-15T12:54:43.000Z - 7 weeks ago

CG Oncology reports first results from CORE-008 Cohort CX

May 15, 2026, 8:00 AM EDT - 7 weeks ago

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

2026-05-14T14:06:13.000Z - 7 weeks ago

CG Oncology price target raised to $82 from $77 at Truist

May 12, 2026, 1:40 PM EDT - 7 weeks ago

CG Oncology Transcript: Bank of America Global Healthcare Conference 2026

May 11, 2026, 4:15 PM EDT - 7 weeks ago

CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

2026-05-11T20:14:26.000Z - 7 weeks ago

CG Oncology price target raised to $81 from $79 at RBC Capital

2026-05-11T17:17:59.000Z - 7 weeks ago

CG Oncology price target raised to $80 from $77 at Wedbush

2026-05-11T13:48:59.000Z - 7 weeks ago

CG Oncology price target raised to $96 from $91 at JPMorgan

2026-05-10T14:30:50.000Z - 7 weeks ago

CG Oncology price target lowered to $83 from $84 at BofA

2026-05-08T17:07:16.000Z - 2 months ago

CG Oncology reports Q1 EPS (71c), consensus (54c)

May 8, 2026, 8:30 AM EDT - 2 months ago

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

May 8, 2026, 8:30 AM EDT - 2 months ago

CG Oncology Earnings release: Q1 2026

May 8, 2026, 8:30 AM EDT - 2 months ago

CG Oncology Quarterly report: Q1 2026

May 5, 2026, 8:00 AM EDT - 2 months ago

CG Oncology to Present at Upcoming Investor Conferences in May

2026-04-27T12:19:01.000Z - 2 months ago

CG Oncology price target raised to $79 from $73 at RBC Capital

Apr 24, 2026, 8:00 AM EDT - 2 months ago

CG Oncology Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

CG Oncology Proxy statement: Proxy filing

2026-04-17T11:20:26.000Z - 2 months ago

JPMorgan ups CG Oncology target, adds ‘Positive Catalyst Watch’

JNJ

2026-04-14T11:50:44.000Z - 2 months ago

CG Oncology price target raised to $84 from $72 at BofA

2026-04-09T15:40:14.000Z - 3 months ago

JPMorgan healthcare analysts hold an analyst/industry conference call

TARA

2026-04-07T09:55:57.000Z - 3 months ago

CG Oncology price target raised to $100 from $80 at H.C. Wainwright

Mar 2, 2026, 3:10 PM EST - 4 months ago

CG Oncology Transcript: TD Cowen 46th Annual Health Care Conference

Feb 27, 2026, 8:30 AM EST - 4 months ago

CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

Feb 27, 2026, 8:30 AM EST - 4 months ago

CG Oncology Annual report: Q4 2025

Feb 27, 2026, 8:30 AM EST - 4 months ago

CG Oncology Earnings release: Q4 2025

Feb 27, 2026, 7:00 AM EST - 4 months ago

CG Oncology Slides: Investor presentation

Feb 23, 2026, 8:00 AM EST - 4 months ago

CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference

Jan 15, 2026, 11:15 AM EST - 6 months ago

CG Oncology Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 6:00 PM EST - 6 months ago

CG Oncology Slides: Investor Presentation

Jan 9, 2026, 8:30 AM EST - 6 months ago

CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC

Jan 6, 2026, 8:00 AM EST - 6 months ago

CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 5, 2025, 8:30 AM EST - 7 months ago

New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer

Nov 26, 2025, 7:00 AM EST - 7 months ago

CG Oncology Announces New Board Member and Board Transition

Nov 14, 2025, 8:00 AM EST - 8 months ago

CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 14, 2025, 8:00 AM EST - 8 months ago

CG Oncology Quarterly report: Q3 2025

Nov 14, 2025, 8:00 AM EST - 8 months ago

CG Oncology Earnings release: Q3 2025

Sep 9, 2025, 7:45 AM EDT - 10 months ago

CG Oncology Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 5, 2025, 10:20 AM EDT - 10 months ago

CG Oncology Transcript: Cantor Global Healthcare Conference 2025

Sep 5, 2025, 7:00 AM EDT - 10 months ago

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

Sep 3, 2025, 8:00 AM EDT - 10 months ago

CG Oncology Completes Enrollment in PIVOT-006

Aug 8, 2025, 8:00 AM EDT - 11 months ago

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 8, 2025, 8:00 AM EDT - 11 months ago

CG Oncology Quarterly report: Q2 2025

Aug 8, 2025, 8:00 AM EDT - 11 months ago

CG Oncology Earnings release: Q2 2025

Jun 10, 2025, 11:20 AM EDT - 1 year ago

CG Oncology Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 5, 2025, 8:00 AM EDT - 1 year ago

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 20, 2025, 11:30 AM EDT - 1 year ago

CG Oncology Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

CG Oncology Slides: Investor Presentation

May 13, 2025, 8:00 AM EDT - 1 year ago

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

May 13, 2025, 8:00 AM EDT - 1 year ago

CG Oncology Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

CG Oncology Earnings release: Q1 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

CG Oncology Transcript: Study Update

Apr 28, 2025, 8:00 AM EDT - 1 year ago

CG Oncology Slides: Study Update

Apr 26, 2025, 4:10 PM EDT - 1 year ago

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

Apr 25, 2025, 8:00 AM EDT - 1 year ago

CG Oncology Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

CG Oncology Proxy statement: Proxy Filing

Mar 28, 2025, 7:00 AM EDT - 1 year ago

CG Oncology Annual report: Q4 2024

Mar 28, 2025, 7:00 AM EDT - 1 year ago

CG Oncology Earnings release: Q4 2024

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

Mar 5, 2025, 11:10 AM EST - 1 year ago

CG Oncology Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 11:10 AM EST - 1 year ago

CG Oncology Slides: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 8:00 AM EST - 1 year ago

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Dec 16, 2024, 4:05 PM EST - 1 year ago

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 12, 2024, 8:19 PM EST - 1 year ago

CG Oncology Announces Pricing of Public Offering

Dec 11, 2024, 7:00 AM EST - 1 year ago

CG Oncology Registration statement: Registration Filing

Dec 11, 2024, 7:00 AM EST - 1 year ago

CG Oncology Registration statement: Registration Filing

Dec 11, 2024, 6:17 AM EST - 1 year ago

CG Oncology Announces Proposed Public Offering

Dec 6, 2024, 1:18 PM EST - 1 year ago

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

Dec 6, 2024, 8:00 AM EST - 1 year ago

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Dec 5, 2024, 8:00 AM EST - 1 year ago

CG Oncology Transcript: Study Result

Dec 5, 2024, 8:00 AM EST - 1 year ago

CG Oncology Press release: Study Result

Dec 5, 2024, 8:00 AM EST - 1 year ago

CG Oncology Slides: Study Result

Dec 5, 2024, 7:00 AM EST - 1 year ago

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Nov 12, 2024, 7:00 AM EST - 1 year ago

CG Oncology Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

CG Oncology Earnings release: Q3 2024

Sep 6, 2024, 10:45 AM EDT - 1 year ago

CG Oncology Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 30, 2024, 8:00 AM EDT - 2 years ago

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 8, 2024, 8:23 AM EDT - 2 years ago

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 8, 2024, 6:00 AM EDT - 2 years ago

CG Oncology Quarterly report: Q2 2024

Aug 8, 2024, 6:00 AM EDT - 2 years ago

CG Oncology Earnings release: Q2 2024

Jun 6, 2024, 12:14 PM EDT - 2 years ago

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

May 24, 2024, 8:00 AM EDT - 2 years ago

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

May 9, 2024, 8:00 AM EDT - 2 years ago

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

May 9, 2024, 7:00 AM EDT - 2 years ago

CG Oncology Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

CG Oncology Earnings release: Q1 2024

May 3, 2024, 4:30 PM EDT - 2 years ago

CG Oncology Transcript: Investor Update

May 3, 2024, 4:30 PM EDT - 2 years ago

CG Oncology Slides: Investor Update

May 3, 2024, 11:23 AM EDT - 2 years ago

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Apr 26, 2024, 8:00 AM EDT - 2 years ago

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

Apr 24, 2024, 10:00 AM EDT - 2 years ago

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

Mar 28, 2024, 8:00 AM EDT - 2 years ago

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Mar 26, 2024, 8:00 AM EDT - 2 years ago

CG Oncology Annual report: Q4 2023

Jan 30, 2024, 7:00 AM EST - 2 years ago

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 29, 2024, 8:14 AM EST - 2 years ago

American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues

BTSG

Jan 26, 2024, 11:50 AM EST - 2 years ago

Biotech's First IPO of 2024 Popped 96%. What It Means.

Jan 25, 2024, 1:46 PM EST - 2 years ago

CG Oncology valued at $1.75 bln in strong market debut

Jan 25, 2024, 7:51 AM EST - 2 years ago

CG Oncology IPO prices above range and boosts share count in bullish move ahead of trading

Jan 24, 2024, 7:10 PM EST - 2 years ago

CG Oncology Announces Pricing of Upsized Initial Public Offering

MorganHoratio Jul. 2 at 9:49 PM

3 · Reply

Buy_SoFi Jul. 2 at 12:00 PM

0 · Reply

BioRich Jul. 1 at 4:46 PM

2 · Reply

Buy_SoFi Jun. 30 at 8:37 PM

$TLTFF <--- MAJOR NEWS!!! 💥 $100 million in financing now accessible! $IBRX $CGON $ENGN $MRK

0 · Reply

forprofit12 Jun. 30 at 1:28 PM

$CGON last trading day of Q2. Weren’t results promised in Q2? Hopefully management has a calendar.

1 · Reply

justiceforb_85 Jun. 30 at 1:06 AM

$CGON re-entered. Looking forward to PIVOT-006 data. If not successful, there is a floor to cretostimogene's value.

2 · Reply

judgeyoung2 Jun. 26 at 7:07 PM

$CGON @tonyctl anything interesting in this flow ?

1 · Reply

Grinding10 Jun. 26 at 4:50 PM

$CGON $65 stock that trades in 50 cent intervals; ok👍

0 · Reply

BIgBill374 Jun. 24 at 11:41 PM

$CGON tape painting or legit sell

1 · Reply

Buy_SoFi Jun. 24 at 5:18 PM

$CGON < $TLTFF

0 · Reply

JuggernautRaider Jun. 24 at 4:10 PM

$CGON finally getting bought? ⭐️

0 · Reply

JuggernautRaider Jun. 22 at 10:14 PM

$CGON or $URGN 🤔

0 · Reply

Grinding10 Jun. 22 at 8:00 PM

$CGON that’s right wake the fuck up we r only getting closer

0 · Reply

Ventureville Jun. 17 at 6:35 PM

Biotech sentiment is heating up. Watching $BVAXF alongside $SAVA, $ALT, $CGON, and $MRNA. One breakthrough can change everything

1 · Reply

SuperGreenToday Jun. 16 at 9:40 PM

$CGON Share Price: $60.24 Contract Selected: Sep 18, 2026 $55 Calls Buy Zone: $10.62 – $13.12 Target Zone: $18.87 – $23.06 Potential Upside: 68% ROI Time to Expiration: 93 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

PhantomZ Jun. 12 at 12:31 AM

$CGON $TLTFF MC only $50 million with one single treatment 65-73% anytime CR vs 75% CR for CG0007 after 15-20 treatments at anytime. The possibilities are endless with Rutherrin! Both are top notch treatments https://www.investing.com/news/transcripts/earnings-call-transcript-theralase-beats-q1-2026-eps-expectations-93CH-4733624

0 · Reply

MarketBeat Jun. 10 at 7:02 AM

https://marketbeat.com/a/8703775/ $CGON CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead

0 · Reply

MarketBeat Jun. 7 at 9:07 PM

https://marketbeat.com/a/8698985/ $CGON CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push

1 · Reply

CapitalMonk Jun. 4 at 11:12 AM

$CGON Price: $54.42 (-2.00%) Trend: Bullish Market Bias (7D): Bullish Bias 📈 Expected Range: ±5.76% RSI: 12.9 | Momentum: Strong Downside Volume: -1.0% vs avg Volatility: 3.17% Support: $54.02 | Resistance: $75.50 Data and analytics sourced from Given Analytics educational research: https://www.givenanalytics.com/

0 · Reply

BIgBill374 Jun. 3 at 1:17 PM

$CGON so a tx for cancer is not good enough anymore maybe we need to say we treat AI cancer protection the machines

1 · Reply

Grinding10 Jun. 2 at 7:46 PM

$CGON fucking joke $20 off Highs what 2 weeks ago

1 · Reply

Grinding10 Jun. 2 at 4:12 PM

$CGON and there’s 3 months of stock progress after a positive readout not even the one we r waiting for; sure why not makes sense as usual 🖕

0 · Reply

Market Cap	6.21B
Revenue (ttm)	4.04M
Net Income (ttm)	-161.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,985.15%
Debt to Equity Ratio	0.00

Volume	792,300
Avg Vol	1,051,682
Day's Range	N/A - N/A
Shares Out	88.20M
Stochastic %K	57%
Beta	0.22
Analysts	Strong Sell
Price Target	$90.28